TRCT
INBX icon

Tower Research Capital (TRC)’s Inhibrx INBX Stock Holding History

Tower Research Capital (TRC)’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$41.7K Sell
440
-948
-68% -$95K ﹤0.01% 2887
2026
Q1 		$93.3K Buy
1,388
+729
+111% +$54.1K ﹤0.01% 2238
2025
Q4 		$52.1K Sell
659
-384
-37% -$26.2K ﹤0.01% 2393
2025
Q3 		$35.1K Sell
1,043
-1,173
-53% -$28.9K ﹤0.01% 2804
2025
Q2 		$31.6K Buy
2,216
+1,347
+155% +$17.4K ﹤0.01% 3357
2025
Q1 		$12.2K Sell
869
-98
-10% -$1.33K ﹤0.01% 3461
2024
Q4 		$14.9K Buy
967
+74
+8% +$1.13K ﹤0.01% 3438
2024
Q3 		$14K Sell
893
-2,009
-69% -$28.2K ﹤0.01% 3484
2024
Q2 		$41.1K Buy
+2,902
New +$45.3K ﹤0.01% 3240

Other funds holding INBX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Tower Research Capital (TRC)'s INBX Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Inhibrx (INBX) stake by 68% in Q2 2026, selling an estimated $95K and leaving 440 shares worth $41.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2887.

Tower Research Capital (TRC) first reported a position in INBX in Q2 2024 and has held it in 9 quarters since. The position peaked at $93.3K in Q1 2026. 162 funds tracked by Wall St. Rank hold INBX as of Q2 2026.

  • Tower Research Capital (TRC) held 440 shares of Inhibrx worth $41.7K as of Q2 2026.
  • Tower Research Capital (TRC) sold 948 Inhibrx shares in Q2 2026, an estimated $95K.
  • Inhibrx made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #2887 holding.
  • Tower Research Capital (TRC) first reported a position in Inhibrx in Q2 2024 and has held it in 9 quarters since.
  • Tower Research Capital (TRC)'s Inhibrx position peaked at $93.3K in Q1 2026.
  • 162 funds tracked by Wall St. Rank held Inhibrx as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.